Pfizer used its ESMO presentation of the Phase 3 SigVie-002 study to argue that sigvotatug vedotin, the integrin beta6-directed antibody-drug conjugate it acquired with Seagen, still has a future in lung cancer despite failing the trial’s primary endpoint. Endpoints News reported on October 25 that a post-hoc analysis of patients treated in the second line showed a 2.5 month overall survival edge for the ADC over docetaxel. That specific figure is reported here as Endpoints reported it; it has not been corroborated by a second independent source in this run and is graded accordingly.
The underlying trial result is not in dispute. Pfizer announced on June 22, 2026 that SigVie-002, which randomised 703 patients with previously treated non-squamous non-small cell lung cancer to sigvotatug vedotin or docetaxel, did not meet its primary endpoint of overall survival in the overall population. At that time Pfizer noted a stronger trend in the prespecified subgroup of patients who had received only one prior line of therapy, about two-thirds of participants, which is the population the ESMO post-hoc analysis examines.
The distinction between prespecified and post-hoc is the whole story. A prespecified subgroup is a hypothesis the trial was designed to test; a post-hoc cut is chosen after the data are known, and its survival edge carries no statistical protection against chance. Pfizer’s own development path reflects that status: the company is continuing sigvotatug vedotin in earlier settings, including a Phase 3 combination with pembrolizumab in first-line disease, rather than filing on SigVie-002.
For readers, the correct weight is narrow. The failed primary endpoint stands. The second-line signal is a reason the program continues, not evidence that the drug prolongs life in any population regulators would accept.